Mayne Pharma Group Ltd (OTCPK:MAYNF)

Full Year 2025 Mayne Pharma Group Ltd Earnings Call Transcript

Aug 28, 2025 / 11:30 PM GMT

Release Date Price: $3.29

Transcript

Key Points

Positve

Mayne Pharma Group Ltd (MAYNF) reported a 5% increase in revenue to AUD 408.1 million, driven by strong performances in women's health.
Gross margin expanded to 60.6%, up from 56.3% in FY24, reflecting a higher contribution from women's health and improved product mix in dermatology.
Operating cash flow from continuing operations increased by 460% to AUD 45.4 million, driven by higher profitability and careful working capital management.
The women's health segment saw a 23% revenue increase, with products like Nextelis, Bajuba, and Vexi showing significant growth.
The company completed a major modernization upgrade at its Salisbury manufacturing facility, improving production capability and efficiency.

Negative

Dermatology revenues declined due to competitive pressures and a shift from branded to generic offerings.
Cash and marketable securities decreased to AUD 100.4 million from AUD 149.3 million last year, partly due to strategic acquisitions and class action settlements.
The international segment's direct contributions declined by 17%, reflecting product mix changes and increased operational expenses.
The company faced temporary supply constraints for some products in the women's health segment, impacting growth.
The dermatology segment experienced a 12% decline in revenues, with competitive launches impacting profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MYX.AX - Mayne Pharma Group Ltd
Full Year 2025 Mayne Pharma Group Ltd Earnings Call
Aug 28, 2025 / 11:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you and thank you all for joining. My name is Sean Patrick O'Brien, and I am the CEO and managing director of Maine Pharma.

Today we're here to present our financial results for the 12 months ended 30th of June 2025, mainly FY25.

Joining me on the call this morning is Maine farmer CFO Aaron Gray.

Today our focus will be on presenting our FY financial results.

We will also briefly update on the scheme of arrangement with Cossette Pharmaceuticals under which Cossett agreed to acquire 100% of the shares of Maine Pharma for $7.40 cash per share.

There will be no Q&A at the end of today's presentation.

Looking at slide 2 is our standard disclaimer. Today's

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.